相似文献
1
How do you know?
Br J Ophthalmol. 2004 Aug;88(8):980-1. doi: 10.1136/bjo.2004.042986.
2
Change in Visual Function in Uveitis Patients after Treatment: An Experience from Nepal.
Ocul Immunol Inflamm. 2018;26(5):747-752. doi: 10.1080/09273948.2016.1264610. Epub 2016 Dec 23.
3
Clinical Features and Visual Outcome of Uveitis in Japanese Patients Younger than 18 Years.
Ocul Immunol Inflamm. 2021 Nov 17;29(7-8):1280-1286. doi: 10.1080/09273948.2020.1726972. Epub 2020 Mar 12.
4
Laser interferometry and visual prognosis in uveitis.
Ophthalmology. 1985 Nov;92(11):1567-9. doi: 10.1016/s0161-6420(85)33835-6.
5
Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.
Clin Exp Med. 2016 May;16(2):125-36. doi: 10.1007/s10238-015-0345-6. Epub 2015 Mar 28.
6
[Uveitis: From diagnosis to treatment].
Rev Med Interne. 2018 Sep;39(9):673-675. doi: 10.1016/j.revmed.2018.02.023. Epub 2018 Mar 27.
7
Can we be more objective in determining the response to treatment in uveitis patients aside from recording anterior chamber reaction?
Ocul Immunol Inflamm. 2009 Jul-Aug;17(4):265-6. doi: 10.1080/09273940802702587.
8
Treating uveitis-associated hypotony with pars plana vitrectomy and silicone oil injection.
Retina. 2010 Jan;30(1):140-5. doi: 10.1097/IAE.0b013e3181b32f06.
9
Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy.
Pediatr Rheumatol Online J. 2018 Aug 6;16(1):51. doi: 10.1186/s12969-018-0266-5.
10
Immunocompetence and transfer factor therapy in uveitis.
Br J Ophthalmol. 1980 May;64(5):332-8. doi: 10.1136/bjo.64.5.332.
引用本文的文献
1
Metabolomic analysis of human vitreous humor differentiates ocular inflammatory disease.
Mol Vis. 2009 Jun 13;15:1210-7.
2
Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis.
Br J Ophthalmol. 2007 Feb;91(2):154-6. doi: 10.1136/bjo.2006.105528. Epub 2006 Sep 14.
本文引用的文献
1
An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Clin Ther. 2003 Oct;25(10):2487-505. doi: 10.1016/s0149-2918(03)80313-2.
2
Trends in size and treatment of recently diagnosed choroidal melanoma, 1987-1997: findings from patients examined at collaborative ocular melanoma study (COMS) centers: COMS report no. 20.
Arch Ophthalmol. 2003 Aug;121(8):1156-62. doi: 10.1001/archopht.121.8.1156.
3
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
Arthritis Rheum. 2003 Aug;48(8):2224-33. doi: 10.1002/art.11104.
4
High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial.
Arch Ophthalmol. 2003 Jul;121(7):944-9. doi: 10.1001/archopht.121.7.944.
5
Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate.
Arch Ophthalmol. 2003 Apr;121(4):437-40. doi: 10.1001/archopht.121.4.437.
6
Natalizumab for active Crohn's disease.
N Engl J Med. 2003 Jan 2;348(1):24-32. doi: 10.1056/NEJMoa020732.
7
An open study of B lymphocyte depletion in systemic lupus erythematosus.
Arthritis Rheum. 2002 Oct;46(10):2673-7. doi: 10.1002/art.10541.
8
The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.
Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30. doi: 10.1001/archopht.120.6.714.
9
Effect of infliximab on sight-threatening panuveitis in Behçet's disease.
Lancet. 2001 Jul 28;358(9278):295-6. doi: 10.1016/s0140-6736(01)05497-6.
10
Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.
N Engl J Med. 2000 Mar 2;342(9):613-9. doi: 10.1056/NEJM200003023420902.
Zotero 插件